Marine Drugs (Sep 2021)

A Marine λ-Oligocarrageenan Inhibits Migratory and Invasive Ability of MDA-MB-231 Human Breast Cancer Cells through Actions on Heparanase Metabolism and MMP-14/MMP-2 Axis

  • Rémi Cousin,
  • Hugo Groult,
  • Chanez Manseur,
  • Romain Ferru-Clément,
  • Mario Gani,
  • Rachel Havret,
  • Claire Toucheteau,
  • Grégoire Prunier,
  • Béatrice Colin,
  • Franck Morel,
  • Jean-Marie Piot,
  • Isabelle Lanneluc,
  • Kévin Baranger,
  • Thierry Maugard,
  • Ingrid Fruitier-Arnaudin

DOI
https://doi.org/10.3390/md19100546
Journal volume & issue
Vol. 19, no. 10
p. 546

Abstract

Read online

Sugar-based molecules such as heparins or natural heparan sulfate polysaccharides have been developed and widely studied for controlling heparanase (HPSE) enzymatic activity, a key player in extracellular matrix remodelling during cancer pathogenesis. However, non-enzymatic functions of HPSE have also been described in tumour mechanisms. Given their versatile properties, we hypothesized that sugar-based inhibitors may interfere with enzymatic but also non-enzymatic HPSE activities. In this work, we assessed the effects of an original marine λ-carrageenan derived oligosaccharide (λ-CO) we previously described, along with those of its native counterpart and heparins, on cell viability, proliferation, migration, and invasion of MDA-MB-231 breast cancer cells but also of sh-MDA-MB-231 cells, in which the expression of HPSE was selectively downregulated. We observed no cytotoxic and no anti-proliferative effects of our compounds but surprisingly λ-CO was the most efficient to reduce cell migration and invasion compared with heparins, and in a HPSE-dependent manner. We provided evidence that λ-CO tightly controlled a HPSE/MMP-14/MMP-2 axis, leading to reduced MMP-2 activity. Altogether, this study highlights λ-CO as a potent HPSE “modulator” capable of reducing not only the enzymatic activity of HPSE but also the functions controlled by the HPSE levels.

Keywords